The present study corroborates the notion that the Flt3-ITD—which in this case was combined with an Npm1 mutation in order to reveal its leukemogenic potential—renders AML LSCs sensitive to the inhibitory effects of atRA. Here, NPM1 is linked to acute myeloid leukemia.